Resistant hypertension is defined as the failure to reach blood pressure control in patients who are adherent to full doses of an appropriate three-drug regimen (including a diuretic). Adherence is a major issue: the rate of partial or complete noncompliance probably approaches 50% in this group of patients; doxazosin, spironolactone, and hydrochlorothiazide were particularly unpopular in one Eastern European study based on drug assay. In the approach to resistant hypertension, the clinician should first confirm compliance and rule out “white coat hypertension,” ideally using ambulatory or home-based measurement of blood pressure. Exacerbating factors should be considered (as outlined above). Finally, identifiable causes of resistant hypertension should be sought (Table 11–14). The clinician should pay particular attention to the type of diuretic being used in relation to the patient’s kidney function. Aldosterone may play an important role in resistant hypertension and aldosterone receptor blockers can be very useful. If goal blood pressure cannot be achieved following completion of these steps, consultation with a hypertension specialist should be considered. Renal sympathetic nerve ablation is a consideration for these patients in the absence of other options, but further trials are needed before this procedure can be routinely integrated into clinical practice.
Table 11–14.Causes of resistant hypertension. ||Download (.pdf) Table 11–14. Causes of resistant hypertension.
Improper blood pressure measurement
Volume overload and pseudotolerance
Excess sodium intake
Volume retention from kidney disease
Inadequate diuretic therapy
Drug-induced or other causes
NSAIDs; cyclooxygenase-2 inhibitors
Cocaine, amphetamines, other illicit drugs
Sympathomimetics (decongestants, anorectics)
Cyclosporine and tacrolimus
Licorice (including some chewing tobacco)
Selected over-the-counter dietary supplements and medicines (eg, ephedra, ma huang, bitter orange)
Excess alcohol intake
Identifiable causes of hypertension (see Table 11–2)
et al. Diagnosis and management of resistant hypertension: state of the art. Nat Rev Nephrol. 2018;14:428.